Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.

doi:10.1016/j.ebiom.2017.08.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.

EBioMedicine - 1 Sept 2017

Kimura Kiminori, Ikoma Akemi, Shibakawa Maki, Shimoda Shinji, Harada Kenichi, Saio Masanao, Imamura Jun, Osawa Yosuke, Kimura Masamichi, Nishikawa Koji, Okusaka Takuji, Morita Satoshi, Inoue Kazuaki, Kanto Tatsuya, Todaka Koji, Nakanishi Yoichi, Kohara Michinori, Mizokami Masashi

Abstract excerpt

BACKGROUND: There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. METHODS: In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Liver Function Tests

Share to Pyrimidinones

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 28844410
DOI: 10.1016/j.ebiom.2017.08.016
PMCID: PMC5605374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.PMID 28844410Read ↗

Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study.Semantic proximity Read ↗

Novel therapies and potential therapeutic targets in the management of chronic hepatitis B.Semantic proximity Read ↗

Management of HCV in cirrhosis-a rapidly evolving landscape.Semantic proximity Read ↗

Rationale and targets for antifibrotic therapies.Semantic proximity Read ↗

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.Semantic proximity Read ↗

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver DiseaseSemantic proximity Read ↗

A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.Semantic proximity Read ↗

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSemantic proximity Read ↗

TGF-β signaling pathway as a pharmacological target in liver diseasesSemantic proximity Read ↗

Beclabuvir for the treatment of hepatitis C.Semantic proximity Read ↗

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.Semantic proximity Read ↗

Host-targeting agents in the treatment of hepatitis C: A beginning and an end?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.